

In the claims:

---

Claim 1 (cancelled)

Claim 2 (currently amended): A method for modulating cell proliferation activation of an NFkB signaling pathway in a cell comprising contacting a cell with an a polypeptide agent that modulates the activity of a TRADE $\alpha$  polypeptide comprising a TRADE $\alpha$  polypeptide sequence at least 90% identical to SEQ ID NO:2 or a TRADE $\beta$  polypeptide sequence at least 90% identical to SEQ ID NO:4, such that cell proliferation activation of an NFkB signaling pathway is modulated.

Claim 3 (currently amended) The method of claim 1 or 2, wherein the cell is selected from the group consisting of: an epithelial cell, a ductal epithelial cell, and a bronchial epithelial cell.

Claim 4 (cancelled)

Claim 5 (currently amended): The method of claim 1 or 2, wherein the cell is selected from the group consisting of: a lung cell, a liver cell, and a brain cell, and a prostate cell.

Claim 6 (currently amended): The method of claim 2, wherein the polypeptide agent is a soluble form of a TRADE $\alpha$  polypeptide comprising a mature TRADE $\alpha$  polypeptide extracellular domain.

Claim 7 (currently amended): The method of claim 6, wherein the soluble form of the TRADE $\alpha$  polypeptide is a TRADE $\alpha$ -Fc fusion protein.

Claim 8 (currently amended): The method of claim 2, wherein the polypeptide agent consists essentially of a TRADE $\alpha$  polypeptide extracellular domain.

Claims 9-38 (cancelled)

Claim 39 (newly added): The method of claim 7, wherein said TRADE $\alpha$ -Fc fusion protein includes the hinge -C<sub>H</sub>2-C<sub>H</sub>3 regions of a human immunoglobulin.

Claim 40 (newly added): The method of claim 7, wherein said TRADE $\alpha$ -Fc fusion protein is an isotype selected from the group consisting of  $\gamma$ 1,  $\gamma$ 2,  $\gamma$ 3,  $\epsilon$  and  $\alpha$ .

Claim 41 (newly added): The method of claim 7, wherein a spacer region of glycine and serine residues are incorporated between the TRADE $\alpha$  and Fc sequences.

Claim 42 (newly added): The method of claim 2, wherein the polypeptide agent is a TRADE $\alpha$  polypeptide sequence comprising a sequence at least 80% identical to amino acids 1-168 of SEQ ID NO:2.

Claim 43 (newly added): The method of claim 2, wherein the polypeptide agent is a TRADE $\alpha$  polypeptide sequence comprising a sequence at least 90% identical to amino acids 1-168 of SEQ ID NO:2.

Claim 44 (newly added): The method of claim 2, wherein the polypeptide agent is a TRADE $\alpha$  polypeptide sequence comprising amino acids 1-168 of SEQ ID NO:2.

Claim 45 (newly added): The method of claim 2, wherein the polypeptide agent is a TRADE $\alpha$  polypeptide sequence comprising at least one of the domains corresponding to amino acids 29-63 of SEQ ID NO:2, amino acids 72-114 of SEQ ID NO:2, amino acids 114-139 of SEQ ID NO:2, or amino acids 137-168 of SEQ ID NO:2.

Claim 46 (newly added) The method of claim 2, wherein the cell is a lung cell.

Claim 47 (newly added): The method of claim 2, wherein the cell is a liver cell

Claim 48 (newly added): The method of claim 2, wherein the cell is a brain cell.

Claim 49 (newly added): The method of claim 2, wherein the polypeptide agent modulates the activity of a TRADE $\alpha$  polypeptide comprising a TRADE $\alpha$  polypeptide sequence at least 95% identical to SEQ ID NO:2 or a TRADE $\beta$  polypeptide comprising a TRADE $\beta$  polypeptide sequence at least 95% identical to SEQ ID NO:4.

Claim 50 (newly added): The method of claim 2, wherein the polypeptide agent modulates the activity of a TRADE $\alpha$  polypeptide comprising a TRADE $\alpha$  polypeptide sequence comprising the amino acid sequence of SEQ ID NO:2 or a TRADE $\beta$  polypeptide comprising the amino acid sequence of SEQ ID NO:4.

Q↓

Claim 51 (newly added): The method of claim 2, wherein the polypeptide agent modulates the activity of a TRADE $\alpha$  polypeptide consisting of the amino acid sequence of SEQ ID NO:2 or a TRADE $\beta$  polypeptide consisting of the amino acid sequence of SEQ ID NO:4.

Claim 52 (newly added): The method of claim 2, wherein contacting said cell with said polypeptide results in reduction of NFkB activity.

Claim 53 (newly added): A method for modulating NFkB activity in a cell comprising contacting a cell with a polypeptide agent comprising a TRADE $\alpha$  polypeptide sequence encoded by a polynucleotide that hybridizes under stringent conditions to the complement of nucleotides 1-504 of SEQ ID NO:1, wherein said polypeptide agent inhibits the activity of a TRADE $\alpha$  polypeptide sequence at least 90% identical to the amino acid sequence of SEQ ID NO:2 or a TRADE $\beta$  polypeptide sequence at least 90% identical to the amino acid sequence of SEQ ID NO:4, such that NFkB activity in said cell is modulated.

Claim 54 (newly added): The method of claim 53, wherein the cell is selected from the group consisting of: a lung cell, a liver cell, and a brain cell.

Claim 55 (newly added) The method of claim 53, wherein the cell is a lung cell.

Claim 56 (newly added): The method of claim 53, wherein the cell is a liver cell

Claim 57 (newly added): The method of claim 53, wherein the cell is a brain cell.

Claim 58 (newly added): The method of claim 53, wherein the TRADE $\alpha$  polypeptide sequence is a soluble form of a TRADE $\alpha$  polypeptide comprising a mature TRADE polypeptide extracellular domain.

Claim 59 (newly added): The method of claim 53, wherein the soluble form of the TRADE $\alpha$  polypeptide sequence is a TRADE $\alpha$ -Fc fusion protein.

Claim 60 (newly added): The method of claim 59, wherein said TRADE $\alpha$ -Fc fusion protein includes the hinge -C<sub>H</sub>2-C<sub>H</sub>3 regions of a human immunoglobulin.

Claim 61 (newly added): The method of claim 59, wherein said TRADE $\alpha$ -Fc fusion protein is an isotype selected from the group consisting of  $\gamma$ 1,  $\gamma$ 2,  $\gamma$ 3,  $\epsilon$  and  $\alpha$ .

Claim 62 (newly added): The method of claim 59, wherein a spacer region of glycine and serine residues are incorporated between the TRADE $\alpha$  polypeptide sequences and Fc sequences.

Claim 63 (newly added): The method of claim 53, wherein the polypeptide agent modulates the activity of a TRADE $\alpha$  polypeptide comprising a TRADE $\alpha$  polypeptide sequence at least 95% identical to SEQ ID NO:2 or a TRADE $\beta$  polypeptide at least 95% identical to SEQ ID NO:4.

Claim 64 (newly added): The method of claim 53, wherein the polypeptide agent modulates the activity of a TRADE $\alpha$  polypeptide comprising the amino acid sequence of SEQ ID NO:2 or a TRADE $\beta$  polypeptide comprising the amino acid sequence of SEQ ID NO:4.

Claim 65 (newly added): The method of claim 53, wherein contacting said cell with said polypeptide results in reduction of NFkB activity.

*are  
cancelled*

---